Drug-induced fatal arrhythmias: Acquired long QT and Brugada syndromes

Isik Turker, Tomohiko Ai, Hideki Itoh, Minoru Horie

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Since the early 1990s, the concept of primary “inherited” arrhythmia syndromes or ion channelopathies has evolved rapidly as a result of revolutionary progresses made in molecular genetics. Alterations in genes coding for membrane proteins such as ion channels or their associated proteins responsible for the generation of cardiac action potentials (AP) have been shown to cause specific malfunctions which eventually lead to cardiac arrhythmias. These arrhythmic disorders include congenital long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, short QT syndrome, progressive cardiac conduction disease, etc. Among these, long QT and Brugada syndromes are the most extensively studied, and drugs cause a phenocopy of these two diseases. To date, more than 10 different genes have been reported to be responsible for each syndrome. More recently, it was recognized that long QT syndrome can be latent, even in the presence of an unequivocally pathogenic mutation (silent mutation carrier). Co-existence of other pathological conditions in these silent mutation carriers may trigger a malignant form of ventricular arrhythmia, the so called torsade de pointes (TdP) that is most commonly brought about by drugs. In analogy to the drug-induced long QT syndrome, Brugada type 1 ECG can also be induced or unmasked by a wide variety of drugs and pathological conditions; so physicians may encounter patients with a latent form of Brugada syndrome. Of particular note, Brugada syndrome is frequently associated with atrial fibrillation whose therapeutic agents such as Vaughan Williams class IC drugs can unmask the dormant and asymptomatic Brugada syndrome. This review describes two types of drug-induced arrhythmias: the long QT and Brugada syndromes.

Original languageEnglish (US)
Pages (from-to)48-59
Number of pages12
JournalPharmacology and Therapeutics
Volume176
DOIs
StatePublished - Aug 1 2017

Fingerprint

Brugada Syndrome
Long QT Syndrome
Cardiac Arrhythmias
Pharmaceutical Preparations
Romano-Ward Syndrome
Channelopathies
Torsades de Pointes
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Ion Channels
Atrial Fibrillation
Genes
Action Potentials
Molecular Biology
Heart Diseases
Electrocardiography
Membrane Proteins
Ions
Physicians
Mutation

Keywords

  • Brugada syndrome
  • Drug-induced arrhythmias
  • Genetic variants
  • Ion channelopathy
  • Long QT syndrome
  • Silent mutation carrier

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Drug-induced fatal arrhythmias : Acquired long QT and Brugada syndromes. / Turker, Isik; Ai, Tomohiko; Itoh, Hideki; Horie, Minoru.

In: Pharmacology and Therapeutics, Vol. 176, 01.08.2017, p. 48-59.

Research output: Contribution to journalReview article

Turker, Isik ; Ai, Tomohiko ; Itoh, Hideki ; Horie, Minoru. / Drug-induced fatal arrhythmias : Acquired long QT and Brugada syndromes. In: Pharmacology and Therapeutics. 2017 ; Vol. 176. pp. 48-59.
@article{e782f9331eca4d93921e5d0024412109,
title = "Drug-induced fatal arrhythmias: Acquired long QT and Brugada syndromes",
abstract = "Since the early 1990s, the concept of primary “inherited” arrhythmia syndromes or ion channelopathies has evolved rapidly as a result of revolutionary progresses made in molecular genetics. Alterations in genes coding for membrane proteins such as ion channels or their associated proteins responsible for the generation of cardiac action potentials (AP) have been shown to cause specific malfunctions which eventually lead to cardiac arrhythmias. These arrhythmic disorders include congenital long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, short QT syndrome, progressive cardiac conduction disease, etc. Among these, long QT and Brugada syndromes are the most extensively studied, and drugs cause a phenocopy of these two diseases. To date, more than 10 different genes have been reported to be responsible for each syndrome. More recently, it was recognized that long QT syndrome can be latent, even in the presence of an unequivocally pathogenic mutation (silent mutation carrier). Co-existence of other pathological conditions in these silent mutation carriers may trigger a malignant form of ventricular arrhythmia, the so called torsade de pointes (TdP) that is most commonly brought about by drugs. In analogy to the drug-induced long QT syndrome, Brugada type 1 ECG can also be induced or unmasked by a wide variety of drugs and pathological conditions; so physicians may encounter patients with a latent form of Brugada syndrome. Of particular note, Brugada syndrome is frequently associated with atrial fibrillation whose therapeutic agents such as Vaughan Williams class IC drugs can unmask the dormant and asymptomatic Brugada syndrome. This review describes two types of drug-induced arrhythmias: the long QT and Brugada syndromes.",
keywords = "Brugada syndrome, Drug-induced arrhythmias, Genetic variants, Ion channelopathy, Long QT syndrome, Silent mutation carrier",
author = "Isik Turker and Tomohiko Ai and Hideki Itoh and Minoru Horie",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.pharmthera.2017.05.001",
language = "English (US)",
volume = "176",
pages = "48--59",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Drug-induced fatal arrhythmias

T2 - Acquired long QT and Brugada syndromes

AU - Turker, Isik

AU - Ai, Tomohiko

AU - Itoh, Hideki

AU - Horie, Minoru

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Since the early 1990s, the concept of primary “inherited” arrhythmia syndromes or ion channelopathies has evolved rapidly as a result of revolutionary progresses made in molecular genetics. Alterations in genes coding for membrane proteins such as ion channels or their associated proteins responsible for the generation of cardiac action potentials (AP) have been shown to cause specific malfunctions which eventually lead to cardiac arrhythmias. These arrhythmic disorders include congenital long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, short QT syndrome, progressive cardiac conduction disease, etc. Among these, long QT and Brugada syndromes are the most extensively studied, and drugs cause a phenocopy of these two diseases. To date, more than 10 different genes have been reported to be responsible for each syndrome. More recently, it was recognized that long QT syndrome can be latent, even in the presence of an unequivocally pathogenic mutation (silent mutation carrier). Co-existence of other pathological conditions in these silent mutation carriers may trigger a malignant form of ventricular arrhythmia, the so called torsade de pointes (TdP) that is most commonly brought about by drugs. In analogy to the drug-induced long QT syndrome, Brugada type 1 ECG can also be induced or unmasked by a wide variety of drugs and pathological conditions; so physicians may encounter patients with a latent form of Brugada syndrome. Of particular note, Brugada syndrome is frequently associated with atrial fibrillation whose therapeutic agents such as Vaughan Williams class IC drugs can unmask the dormant and asymptomatic Brugada syndrome. This review describes two types of drug-induced arrhythmias: the long QT and Brugada syndromes.

AB - Since the early 1990s, the concept of primary “inherited” arrhythmia syndromes or ion channelopathies has evolved rapidly as a result of revolutionary progresses made in molecular genetics. Alterations in genes coding for membrane proteins such as ion channels or their associated proteins responsible for the generation of cardiac action potentials (AP) have been shown to cause specific malfunctions which eventually lead to cardiac arrhythmias. These arrhythmic disorders include congenital long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, short QT syndrome, progressive cardiac conduction disease, etc. Among these, long QT and Brugada syndromes are the most extensively studied, and drugs cause a phenocopy of these two diseases. To date, more than 10 different genes have been reported to be responsible for each syndrome. More recently, it was recognized that long QT syndrome can be latent, even in the presence of an unequivocally pathogenic mutation (silent mutation carrier). Co-existence of other pathological conditions in these silent mutation carriers may trigger a malignant form of ventricular arrhythmia, the so called torsade de pointes (TdP) that is most commonly brought about by drugs. In analogy to the drug-induced long QT syndrome, Brugada type 1 ECG can also be induced or unmasked by a wide variety of drugs and pathological conditions; so physicians may encounter patients with a latent form of Brugada syndrome. Of particular note, Brugada syndrome is frequently associated with atrial fibrillation whose therapeutic agents such as Vaughan Williams class IC drugs can unmask the dormant and asymptomatic Brugada syndrome. This review describes two types of drug-induced arrhythmias: the long QT and Brugada syndromes.

KW - Brugada syndrome

KW - Drug-induced arrhythmias

KW - Genetic variants

KW - Ion channelopathy

KW - Long QT syndrome

KW - Silent mutation carrier

UR - http://www.scopus.com/inward/record.url?scp=85019888047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019888047&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2017.05.001

DO - 10.1016/j.pharmthera.2017.05.001

M3 - Review article

C2 - 28527921

AN - SCOPUS:85019888047

VL - 176

SP - 48

EP - 59

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -